Anti-angiogenic nanotherapy via active targeting systems to tumors and adipose tissue vasculature.
Sophisticated drug delivery systems (DDS) are required for delivering drugs, especially macromolecules such as nucleic acids or proteins, to their sites of action. Therefore it is a prerequisite that future DDS are designed to selectively target a tissue. In this review, we focus on systems that actively target the vasculature in tumors or adipose tissues. For targeting tumor vasculatur, a new strategy referred to as dual-targeting is proposed that uses a combination of a receptor specific ligand and a cell penetrating peptide, which can induce the synergistic enhancement of tissue selectivity under in vivo conditions. A novel pH-sensitive cationic lipid was designed to enhance the endosomal release of encapsulated compounds such as siRNA as well as to improve the stability in blood circulation after intravenous administration. A cyclic RGD peptide is used as an active targeting ligand. For targeting adipose vasculature, prohibitin, which is expressed on the surface of adipose endothelial cells, was targeted with KGGRAKD peptides on the surface of PEGylated nanoparticles. Prohibitin targeted nanoparticles (PTNP) encapsulating Cytochrome c (CytC) can selectively target adipose vasculature by optimizing the lengths of the PEG linkers and can deliver CytC to adipose endothelial cells. PTNP can successfully induce anti-obese effects as well as apoptosis by delivering CytC to the cytosol in endothelial cells. Unexpectedly, the EPR (enhanced permeability and retention) effect, which is usually observed in tumor tissue, was also observed in the adipose vasculature, especially in obese mice, where PEGylated nanoparticles can pass through the endothelial barriers in adipose tissue. We believe that these achievements in active targeting will allow a greatly expanded use of DDS for nanomedicines.
Faculty of Pharmaceutical Sciences, Hokkaido University, Japan. harasima@pharm.hokudai.ac.jp.
Yu
Y
Sakurai
Kazuaki
K
Kajimoto
Hideyoshi
H
Harashima
D017667:Adipocytes / Q000737:chemistry* / Q000378:metabolism; D000273:Adipose Tissue / Q000166:cytology; D020533:Angiogenesis Inhibitors / Q000737:chemistry* / Q000378:metabolism; D000818:Animals; D057846:Cell-Penetrating Peptides / Q000737:chemistry* / Q000378:metabolism*; D045304:Cytochromes c / Q000737:chemistry* / Q000378:metabolism; D016503:Drug Delivery Systems; D042783:Endothelial Cells / Q000737:chemistry* / Q000166:cytology; D006863:Hydrogen-Ion Concentration; D008024:Ligands; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes / Q000737:chemistry; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D009369:Neoplasms / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy*; D009842:Oligopeptides / Q000737:chemistry* / Q000378:metabolism; D034741:RNA, Small Interfering / Q000737:chemistry* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D057846:Cell-Penetrating Peptides; D008024:Ligands; D008055:Lipids; D008081:Liposomes; D009842:Oligopeptides; D034741:RNA, Small Interfering; D045304:Cytochromes c